Avecho Biotechnology (AVE) H1 2026 earnings summary

Executive summary

• Focused on developing and commercializing Human and Animal Health products using proprietary TPM® drug delivery technology, with a lead asset in Phase III clinical trials for insomnia treatment.

• Achieved a key milestone as the Data Monitoring Board recommended continuation of the pivotal Phase III trial without increasing sample size, supporting the robustness of the study.

• Recruitment for the remaining trial participants is expected to complete within 12 months, with additional clinical sites being activated.

Financial highlights

• Revenue from ordinary activities fell 89% year-over-year to $59,602, reflecting variable product sales.

• Loss after tax decreased 28% year-over-year to $1,923,629 (prior period: $2,675,960).

• Research and development tax incentive and other income rose 74% to $1,375,397, mainly from R&D tax incentives.

• Operating expenses decreased 13% to $3,343,105, driven by lower R&D expenditure.

• Cash and cash equivalents at period end were $6,609,515, up from $4,663,491 at 31 December 2025.

Outlook and guidance

• Directors believe current cash reserves and working capital are sufficient to fund operations and R&D for at least 12 months.

• The company retains flexibility to reduce discretionary spending and has a history of successful capital raising and grant eligibility.